Navigation Links
Reportlinker Adds Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential
Date:3/29/2011

NEW YORK, March 29, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential

http://www.reportlinker.com/p0357074/Nanotechnology-in-Drug-Delivery---Technological-Improvements-and-Novel-Approaches-to-Fulfill-High-Potential.html

Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential

Summary

GBI Research, the leading business intelligence provider, has released its latest report, "Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential" that provides key data, information and analysis of the major trends and issues in Nanotechnology in Drug Delivery market. The report provides a comprehensive insight into the role of Nanotechnology in Drug Delivery. The report also provides a detailed analysis of market characterization of nanotechnology in drug delivery market in terms of its market size, segmentation by key geography types and the major market drivers and barriers. The report also talks about the technological trends over the years in use of nanotechnology in drug delivery.

Scope

The scope of the report includes -

- Detailed overview of Nanotechnology in Drug Delivery in pharmaceutical industry along with their use, efficiency and limitation.

- Annualized market data from 2007 and forecast forward till 2016 along with segmentation by geography.

- Key market drivers and restraints shaping the Nanotechnology in Drug Delivery market.

- Competitive landscape analysis with competitive profiling of leading companies.

- Analysis of partnership deals from 2006 to 2010

- Analysis of M&A deals from 2005 to 2010 along with segmentation by value geography and companies.

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

- Develop better strategies for Nanotechnology in Drug Delivery market by understanding the market dynamics.

- Develop market-entry and market expansion strategies by identifying the key development area

- Understand the factors shaping the Nanotechnology in Drug Delivery

- For understanding the technological trends in the market.

- Identify the key players best positioned to take the advantage of the opportunities in the global market.

- Exploit partnership and acquisition opportunities by identifying the products that could fill the portfolio gaps.

Table of Contents

1 Table of Contents

1 Table of Contents 3

1.1 List of Tables 6

1.2 List of Figures 6

2 Nanotechnology in Drug Delivery – Introduction 7

2.1 Introduction 7

2.2 GBI Research Report Guidance 8

3 Application of Nanotechnology in Drug Delivery 9

3.1 Current Applications of Nano-enabled Drug Delivery 9

3.1.1 Nano-engineered drugs 9

3.1.2 Nano-carriers 10

3.2 Future Applications of Nano-enabled Drug Delivery 11

3.2.1 Gene and Vaccine Delivery 11

3.2.2 Controlled-Release Devices 12

3.2.3 Increased Biocompatibility 12

3.2.4 Improved Drug Bioavailability and Solubility 12

3.2.5 Applied Diagnosis, Etiology, Prognosis and Therapy (ADEPT) 12

3.2.6 Tissue Specific Delivery 12

4 Nanotechnology in Drug Delivery – Case Studies 13

4.1 Abraxis Bioscience, Inc. – Paclitaxel-Albumin Nanoparticles (Abraxane) 13

4.2 Nanospectra Biosciences– AuroShell Particles 13

4.3 Calando Pharmaceuticals, Inc. – RONDEL Technology 13

4.4 Starpharma Holdings, Ltd. – Dendrimer-Based VivaGel 14

4.5 Mersana Therapeutics: Fleximer – Camptothecin Conjugate 14

4.6 Elan Corporation – NanoCrystal Technology 14

5 Nanotechnology in Drug Delivery – Market Characterization 16

5.1 Introduction 16

5.2 Nano-enabled Drug Delivery Market Drivers 16

5.2.1 Clinical Benefits of Nano-enabled Drug delivery 16

5.2.2 Value Addition to Existing Pharmaceutical Products through Reformulation 16

5.2.3 Strong Pipeline Portfolio 16

5.3 Nano-Enabled Drug Delivery Market Barriers 17

5.3.1 Poor R&D Facilities and Time Gap between Research and Commercialization 17

5.3.2 Lack of Consistent Policy on Technology Transfer and Lack of Capacity to Produce Products 17

5.3.3 Regulatory Hindrance 17

5.4 Opportunity and Unmet Need – Drug Delivery 18

5.4.1 Opportunities 18

5.4.2 Unmet Need 18

5.5 Selected Nano-Enabled Therapeutics Approved by the FDA 20

5.5.1 Doxil (Caelyx) 20

5.5.2 Abraxane 21

5.5.3 AmBisome 22

5.5.4 Diprivan 23

5.5.5 Triglide 24

5.5.6 Myocet 25

5.5.7 DepoCyt 26

5.5.8 DaunoXome 27

5.5.9 Estrasorb 27

5.5.10 Macugen 28

5.5.11 Abelcet 29

5.5.12 Adagen 30

5.5.13 Pegasys 30

5.5.14 Somavert 32

5.5.15 Neulasta 33

5.5.16 Copaxone 34

5.5.17 Amphotec 35

5.5.18 PegIntron 35

5.5.19 Oncaspar 37

5.5.20 Epaxal 38

5.5.21 Elestrin 38

6 Nanotechnology in Drug Delivery – Trend Analysis 40

6.1 Increasing Government Funding for Nanotechnology R&D 40

6.2 Increasing Seed and Early-Stage Venture Capital 40

6.3 Creation of a New Registration Category for Nanotechnology Products within the USPTO 40

6.4 Genericization and Emerging Business Models Driving a Need for Novel Drug Delivery Methods 41

7 Nanotechnology in Drug Delivery – Regulatory Landscape 42

7.1 Introduction 42

7.2 Europe 44

7.2.1 REACH Regulation 44

7.2.2 European Medicines Agency 46

7.3 The US 46

7.3.1 Environment Protection Agency 46

7.3.2 Food and Drug Administration 47

7.3.3 National Institute of Occupational Safety and Health 47

7.4 Japan 48

8 Nanotechnology in Drug Delivery – Pipeline Analysis 49

8.1 Overview 49

8.1.1 Pipeline Analysis by Phase 50

9 Nanotechnology in Drug Delivery – Strategic Consolidations 55

9.1 Overview 55

9.2 Mergers and Acquisitions 55

9.2.1 Mergers and Acquisitions by Geography 55

9.2.2 Mergers and Acquisitions by Deal value 56

9.2.3 Mergers and Acquisition Analysis by Deal Type 57

9.3 Summary of Major M&A Deals 58

9.3.1 AstraZeneca Acquires MedImmune 58

9.3.2 Pfizer Completes Acquisition of Wyeth 58

9.3.3 Celgene Announces To Acquire Abraxis BioScience 58

9.3.4 Amgen Acquires Abgenix 59

9.3.5 Teva Pharmaceutical Acquires Ivax 59

9.4 Licensing Agreement 60

9.4.1 Deals by Year of Consolidations 60

9.4.2 Deals by Geography 61

9.4.3 Deals by Deal value 62

9.5 Summary of Major M&A Deals 62

9.5.1 AstraZeneca Enters Into Collaboration and Licensing Agreement with Targacept 62

9.5.2 AstraZeneca Enters into Licensing Agreement with Rigel Pharmaceuticals 63

9.5.3 Isis Pharmaceuticals Enters Into Licensing Agreement with Genzyme 63

9.5.4 Nektar Therapeutics Enters Into Licensing Agreement with AstraZeneca 63

9.5.5 Abraxis Enters Into License Agreement With ProMetic Life Sciences 64

10 Nanotechnology in Drug Delivery – Future Players 65

10.1 Overview 65

10.2 Abraxis Bioscience (Abraxis) 66

10.2.1 Overview 66

10.2.2 Business Description 66

10.2.3 Product Portfolio 67

10.3 AlphaRx Corporation 68

10.3.1 Overview 68

10.3.2 Business Description 68

10.3.3 Product Portfolio 69

10.4 Camurus AB 69

10.4.1 Overview 69

10.4.2 Product Portfolio 70

10.5 Eurand 70

10.5.1 Overview 70

10.5.2 Business Description 70

10.5.3 Product Portfolio 71

10.6 NanoBio Corporation 71

10.6.1 Overview 71

10.6.2 Product Portfolio 72

10.7 NanoCarrier 72

10.7.1 Overview 72

10.7.2 Product Portfolio 73

11 Nanaotechnology in Drug Delivery – Appendix 74

11.1 Market Definitions 74

11.2 Abbreviations 74

11.3 Research Methodology 75

11.3.1 Coverage 76

11.3.2 Secondary Research 76

11.3.3 Primary Research 76

11.3.4 Expert Panel Validation 77

11.4 Contact Us 77

11.5 Disclaimer 77

11.6 Sources 77

List of Tables

1.1 List of Tables

Table 1: Elan Pharmaceutical, Drugs Based on NanoCrystal Technology, 2010 15

Table 2: Nanotechnology in Drug Delivery, Global, Regulatory Filing Clinical Pipeline, 2010 50

Table 3: Nanotechnology in Drug Delivery, Global, Phase III Clinical Pipeline, 2010 51

Table 4: Nanotechnology in Drug Delivery, Global, Phase II Clinical Pipeline, 2010 51

Table 5: Nanotechnology in Drug Delivery, Global, Phase I Clinical Pipeline, 2010 52

Table 6: Nanotechnology in Drug Delivery, Global, Preclinical Pipeline, 2010 53

Table 7: Nanotechnology in Drug Delivery, Global, Discovery Pipeline, 2010 54

Table 8: Abraxis BioScience, Inc., Nano-Enabled Drug Delivery Pipeline Products, 2010 67

Table 9: AlphaRx Corporation, Inc., Nano-enabled Drug Delivery Pipeline Products, 2010 69

Table 10: Camurus AB, Inc., Nano-enabled Drug Delivery Pipeline Products, 2010 70

Table 11: Eurand, Inc., Nano-enabled Drug Delivery Pipeline Products, 2010 71

Table 12: NanoBio Corporation, Inc., Nano-enabled Drug Delivery Pipeline Products, 2010 72

Table 13: NanoCarrier, Inc., Nano-enabled Drug Delivery Pipeline Products, 2010 73

List of Figures

1.2 List of Figures

Figure 1: Nanotechnology in Drug Delivery, Comparison of General and Nano-enabled Drugs, 2010 7

Figure 2: Nanotechnology in Drug Delivery, Current Application of Nanotechnology in the Pharmaceutical Industry, 2010 9

Figure 3: Nanotechnology in Drug Delivery, Future Application of Nanotechnology in Drug Pharmaceutical Industry, 2010 11

Figure 4: Nanotechnology in Drug Delivery, Global, Driver and Restraints, 2010 17

Figure 5: Nanotechnology in Drug Delivery, Opportunity and Unmet Needs, 2010 19

Figure 6: Nanotechnology in Drug Delivery, Trend Analysis, 2010 40

Figure 7: Nanotechnology in Drug Delivery, Challenges Facing Regulators Regarding Nanotechnology 43

Figure 8: Nanotechnology in Drug Delivery, Global, Pipeline by Therapy Area (%), 2010 49

Figure 9: Nanotechnology in Drug Delivery, Global, Pipeline by Phase (%), 2010 50

Figure 10: Nanotechnology in Drug Delivery, Global, M&A Deals by Geography (%), (2006-2010) 55

Figure 11: Nanotechnology in Drug Delivery, Global, M&A Deals by Deals Value (%), 2006-2010 56

Figure 12: Nanotechnology in Drug Delivery, Global, M&A Deals by Deals Type (%), 2006-2010 57

Figure 13: Nanotechnology in Drug Delivery, Global, Licensing Agreements by Years of Consolidation (%), 2006-2010 60

Figure 14: Nanotechnology in Drug Delivery, Global, Licensing Agreements by Geography (%), 2006-2010 61

Figure 15: Nanotechnology in Drug Delivery, Global, Licensing Agreements by Deals Value (%), 2006-2010 62

Figure 16: Nanotechnology in Drug Delivery, Global, Clinical Pipeline by Company, 2010 65

To order this report:

: Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Reportlinker Adds Assistive Devices for Special Needs: Technologies and Global Markets
2. Reportlinker Adds Triple Analysis: Colorectal Cancer, Leukemia and Pancreatic Cancer
3. Reportlinker Adds Triple Analysis: Colorectal Cancer, Lung Cancer and Lymphoma
4. Reportlinker Adds Therapeutics for Immune System Disorders
5. Reportlinker Adds Process Analytical Technologies for Pharmaceuticals: Global Markets
6. Reportlinker Adds RNAi Drug Delivery: Technologies and Global Markets
7. Reportlinker Adds Global Vitamins Industry
8. Reportlinker Adds US Medical Adhesives And Sealants Industry
9. Reportlinker Adds Global Microscopes Industry
10. Reportlinker Adds Global Imaging Agents Industry
11. Reportlinker Adds Global Stethoscopes Industry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... , Feb. 10, 2016  Visage Imaging Inc. ... Ltd. (ASX: PME), has announced that the American College ... (UF) have selected the Visage 7 Enterprise Imaging ... the Emergent/Critical Care Imaging SIMulation (SIM). SIM is ... Imaging Program (WIDI), a multi-faceted and fully-integrated online ...
(Date:2/10/2016)... DIEGO , Feb. 10, 2016 ... company developing novel, clinical-stage therapies for sickle cell disease ... underwritten public offering of 29,090,910 units at a price ... consists of one share of the Company,s common stock ... Company,s common stock at an exercise price of $0.42 ...
(Date:2/10/2016)... Antibacterial Drugs Market - Global Industry ... ", reveals that the global antibacterial drugs market is forecast ... owing to patent expiries of blockbuster drugs. Even though the ... forecast period, the value is anticipated to decline from US$43.9 ... Antibacterial Drugs Market - Global Industry Analysis, Size, Share, ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... February 10, 2016 , ... Intermedix ... of Emergency Medicine , an emergency medicine professional association, to support the organization's ... , The American Academy of Emergency Medicine, or AAEM, seeks to empower emergency ...
(Date:2/10/2016)... SAN FRANCISCO, Calif. (PRWEB) , ... February 10, 2016 , ... ... category: Best Water Brand. There were three leading bottled water brand owners that topped ... edge services that enhance connectivity and optimize conversion. The premier brand was Tibet 5100, ...
(Date:2/10/2016)... ... February 10, 2016 , ... Intalere’s 2016 Executive Forum, ... 200 of the country’s top healthcare executives to share insights on transformational strategies ... the Forum is the provider-centric perspective, experience, expertise and strategy shared by the ...
(Date:2/10/2016)... ... 2016 , ... Armune BioScience signed a definitive agreement with ... centers across the country. Launched in April of 2015, Apifiny is the only cancer ... Apifiny order volume exceeded 3,000 tests in 2015. Primary care physicians and urologists have ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... it will attend the Ohio Safety Congress and Expo event March 9-11, 2016. ... the Greater Columbus Convention Center. , As the longest running and largest ...
Breaking Medicine News(10 mins):